Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Boomskidon Feb 24, 2023 9:08am
172 Views
Post# 35302938

My Opinion of poof's Opinion of Chiesi's CHMP Opinion

My Opinion of poof's Opinion of Chiesi's CHMP OpinionPoof reports that Chiesi has received an opinion, not an approval, an opinion, from CHMP. My opinion is that the opinion makes a thin soup. Approvals make positively hearty soups, fattening, even. It's also my opinion that poof's opinion about the CHMP opinion seems a little over the top, especially when he's still pumping the M&M, the Midatech "Merger". 

Basically, in my opinion, poof has written an opinion about a CHMP opinion of a drug that isn't even an xB3 drug, won't be one for a year or two, and has a value placed on it by Bioasis of only $750,000. 

It's also interesting to me that poof says Bioasis has indicated that Hunter data would have been released shortly after Biodexa got going after the "merger".

How about serving up that data right now, for Bioasis. I've opined for months that Bioasis may be holding back news, maybe even holding off business deals, until the "merger" gets done.

Meanwhile, opinions about opinions about LSDs worth only $750,000 each aren't worth much.

But a little xB3 data right about now might begin to make the case that xB3 has more value than Rathjen has been acknowledging this past year. Bioasis shareholders could use a little truth about xB3 these days. 

I like xB3 data far more than I like opinions about opinions offered up to pump a losing "merger".

And that's my opinion about poof"s opinion about CHMP's opinion.

Show us the data! Now! 

jd
<< Previous
Bullboard Posts
Next >>